CD105 blockade restores osimertinib sensitivity in drug-resistant EGFR-mutant non-small cell lung cancer
Carotuximab effectively reduced the slow-cycling cell population and restored osimertinib sensitivity, offering a promising strategy for managing refractory NSCLC.
Authors
- Joseph Lownik (ORCID: https://orcid.org/0000-0002-9025-8210)
- Edwin M. Posadas (ORCID: https://orcid.org/0000-0001-8649-1346)
- K. Nathan Sankar (ORCID: https://orcid.org/0000-0001-8636-8479)
- Karen L. Reckamp (ORCID: https://orcid.org/0000-0002-9213-0325)
- Manish Thiruvalluvan (ORCID: https://orcid.org/0000-0002-7560-4111)
- Sungyong You (ORCID: https://orcid.org/0000-0003-3513-1783)
- Neil A. Bhowmick (ORCID: https://orcid.org/0000-0001-8747-5989)
- Larry Milshteyn (ORCID: https://orcid.org/0000-0002-2286-2133)
- Matthew Gayhart (ORCID: https://orcid.org/0009-0000-5701-9173)
- Manuel J. Arana Rosainz
- X. Li
- Barliz Waissengrin (ORCID: https://orcid.org/0000-0003-0287-5241)
- Sandrine Billet (ORCID: https://orcid.org/0000-0002-6121-5780)
- Anton Villamejor
- Hyoyoung Kim (ORCID: https://orcid.org/0000-0001-8498-9650)
- Zhenqiu Liu
- Jean Lopategui (ORCID: https://orcid.org/0000-0001-9859-0405)
Institutions
- Cedars-Sinai Medical Center (US)
- Radiation Effects Research Foundation (JP)
Publication Details
- Journal
- Drug Resistance Updates
- Published
- 2025-03-12
- DOI
- https://doi.org/10.1016/j.drup.2025.101237
- Citations
- 3
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 4.56